Shots:
- Bio-Thera Solutions & SteinCares signed an agreement to commercialize a proposed dupilumab biosimilar for inflammatory diseases in Latin America
- As per the deal, Bio-Thera will handle product development and supply, while SteinCares manages registration and commercialization in Latin America
- Dupilumab (SC) is a fully human mAb that blocks IL-4 and IL-13 signalling pathways and is not an immunosuppressant
Ref: PRNewswire | Image: Bio-Thera Solutions & SteinCares | Press Release
Related News:- Xcell Biosciences and ThermoFisher Enter Into a Joint Research Collaboration to Advance Cell Therapies
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
